Halofantrine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for halofantrine hydrochloride and what is the scope of freedom to operate?
Halofantrine hydrochloride
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for halofantrine hydrochloride
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 7 |
Patent Applications: | 564 |
DailyMed Link: | halofantrine hydrochloride at DailyMed |
Recent Clinical Trials for halofantrine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Papua New Guinea Institute of Medical Research | Phase 3 |
Lihir Medical Centre | Phase 3 |
Barcelona Institute for Global Health | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for halofantrine hydrochloride
US Patents and Regulatory Information for halofantrine hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | HALFAN | halofantrine hydrochloride | TABLET;ORAL | 020250-001 | Jul 24, 1992 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |